Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Logan Regional Hospital
mi
from
Logan, UT
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Logan Regional Hospital
mi
from
Logan, UT
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Norris Cotton Cancer Center-North
mi
from
Saint Johnsbury, VT
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Norris Cotton Cancer Center-North
mi
from
Saint Johnsbury, VT
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
CCOP - Northwest
mi
from
Tacoma, WA
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Sibley Memorial Hospital
mi
from
Washington, D.C.,
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Sibley Memorial Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated:  5/18/2017
Sands Cancer Center
mi
from
Canandaigua, NY
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Status: Enrolling
Updated: 5/18/2017
Sands Cancer Center
mi
from
Canandaigua, NY
Click here to add this to my saved trials
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment
Status: Enrolling
Updated:  5/18/2017
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment
Status: Enrolling
Updated: 5/18/2017
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment
Status: Enrolling
Updated:  5/18/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment
Status: Enrolling
Updated: 5/18/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated:  5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated: 5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated:  5/18/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated: 5/18/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated:  5/18/2017
Ireland Cancer Center
mi
from
Cleveland, OH
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated: 5/18/2017
Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated:  5/18/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated: 5/18/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated:  5/18/2017
CCOP - Green Bay
mi
from
Green Bay, WI
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
Status: Enrolling
Updated: 5/18/2017
CCOP - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Miami
mi
from
Miami, FL
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Ingalls Cancer Research Center
mi
from
Harvey, IL
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Ingalls Cancer Research Center
mi
from
Harvey, IL
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Kansas
mi
from
Kansas City, KA
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Kansas
mi
from
Kansas City, KA
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Louisianna State University
mi
from
Shreveport, LA
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Louisianna State University
mi
from
Shreveport, LA
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Tufts Medical Center
mi
from
Boston, MA
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Michigan
mi
from
Ann Arbor, MI
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Mississippi
mi
from
Jackson, MS
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Mississippi
mi
from
Jackson, MS
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Ohio State University
mi
from
Columbus, OH
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Vanderbilt University
mi
from
Nashville, TN
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Northwestern University
mi
from
Chicago, IL
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  5/22/2017
Washington University
mi
from
Saint Louis, MO
Everolimus Versus Placebo in Head and Neck Cancer
Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 5/22/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated:  5/22/2017
University of Chicago
mi
from
Chicago, IL
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated: 5/22/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated:  5/22/2017
CRO-National Cancer Institute
mi
from
Aviano,
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated: 5/22/2017
CRO-National Cancer Institute
mi
from
Aviano,
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
St Joseph'S Hospital
mi
from
Los Angeles, CA
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
St Joseph'S Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
University of Miami
mi
from
Miami, FL
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
Hektoen /Stroger Hospital
mi
from
Chicago, IL
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
Hektoen /Stroger Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
Ralph Lauren Center for Cancer Care and Prevention
mi
from
New York, NY
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/22/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/22/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
Status: Enrolling
Updated:  5/22/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
Status: Enrolling
Updated: 5/22/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Brigham and Women's Hospital (BWH)
mi
from
Boston, MA
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Brigham and Women's Hospital (BWH)
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Huntsman Cancer Hospital / University of Utah
mi
from
Salt Lake City, UT
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Huntsman Cancer Hospital / University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials